Duchenne News Tags: PepGen

March 13, 2024
PepGen shares a press release announcing the FDA has granted both orphan drug and rare pediatric disease designations for PGN-EDO51.
January 8, 2024
PepGen announces first patient dosed in its CONNECT1-EDO51 Phase 2, open-label multiple ascending dose clinical trial.
October 17, 2023
PepGen shares Q3 updates via newsletter summary.
July 21, 2023
PepGen shares their 2023 Q2 newsletter
May 19, 2023
PepGen announces clearance by Health Canada of CTA for PGN-EDO51 to begin the Phase 2 Clinical Trial, CONNECT1-EDO51
April 10, 2023
PepGen announces quarterly newsletter on April 7, 2023.
September 28, 2022
PepGen announces the completed results from its Phase 1 healthy normal volunteer (HNV) trial of PGN-EDO51 for Duchenne.

Experience the magic this summer!

How is the rare disease community accomplishing goals?

Tune in on February 29 to hear from our panel and moderators on how they are accomplishing goals and living life to the fullest!

Your gift helps Jett Foundation provide programming and opportunities, such as Camp Promise, to many families impacted by Duchenne muscular dystrophy each year.

Accessible Vehicle Fund Applications Open